Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Inhibitor Therapeutics, Inc. (INTI) had Return on Equity of -46.80% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-0.63M |
|
-- |
|
-- |
|
$0.67M |
|
$-0.67M |
|
$0.04M |
|
$-0.63M |
|
$-0.63M |
|
$-0.63M |
|
$-0.63M |
|
$-0.63M |
|
$-0.63M |
|
$-0.67M |
|
$-0.67M |
|
172.32M |
|
172.32M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$4.42M |
|
-- |
|
$0.08M |
|
$4.51M |
|
$0.09M |
|
-- |
|
$3.06M |
|
$3.15M |
|
$1.35M |
|
$1.35M |
|
$1.35M |
|
172.32M |
|
| Cash Flow Statement Financials | |
$-1.28M |
|
-- |
|
-- |
|
$5.61M |
|
$4.32M |
|
$-1.28M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
46.68 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.28M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-46.80% |
-46.80% |
|
-14.05% |
|
-46.80% |
|
$0.01 |
|
$-0.01 |
|
$-0.01 |
|